Ultrasound for drug and gene delivery to the brain
- PMID: 18486271
- PMCID: PMC2504014
- DOI: 10.1016/j.addr.2008.03.010
Ultrasound for drug and gene delivery to the brain
Abstract
Noninvasive, transient, and local image-guided blood-brain barrier disruption (BBBD) has been demonstrated with focused ultrasound exposure in animal models. Most studies have combined low pressure amplitude and low time average acoustic power burst sonications with intravascular injection of pre-formed micro-bubbles to produce BBBD without damage to the neurons. The BBB has been shown to be healed within a few hours after the exposure. The combination of focused ultrasound beams with MR image guidance allows precise anatomical targeting as demonstrated by the delivery of several marker molecules in different animal models. This method may in the future have a significant impact on the diagnosis and treatment of central nervous system (CNS) disorders. Most notably, the delivery of the chemotherapy agents (liposomal Doxorubicin and Herceptin) has been shown in a rat model.
Figures
References
-
- Abbott NJ, Romero IA. Transporting therapeutics across the blood-brain barrier. Mol Med Today. 1996;2:106–113. - PubMed
-
- Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998;42:1083–1099. - PubMed
-
- Johansson BB. The physiology of the blood-brain barrier. Adv Exp Med Biol. 1990;274:25–39. - PubMed
-
- Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron. 2002;36:555–558. - PubMed
-
- Nag S. Morphology and molecular properties of cellular components of normal cerebral vessels. Methods Mol Med. 2003;89:3–36. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
